Study summary
Obinutuzumab helped more people with lupus kidney disease reach full kidney response
46.4%complete kidney response at 76 weeks, vs 33.1%
What was tested
Obinutuzumab, an antibody that deeply depletes B cells, added to standard therapy, against placebo plus standard therapy, for active lupus nephritis.
What they found
- A complete kidney response occurred in 46.4% vs 33.1%.
- More people were able to lower their steroid dose.
What it means
Adds a third approved drug for lupus nephritis, alongside belimumab and voclosporin.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.